Your browser doesn't support javascript.
loading
Diminished Immune Surveillance during Histologic Progression of Intraductal Papillary Mucinous Neoplasms Offers a Therapeutic Opportunity for Cancer Interception.
Hernandez, Sharia; Parra, Edwin Roger; Uraoka, Naohiro; Tang, Ximing; Shen, Yu; Qiao, Wei; Jiang, Mei; Zhang, Shanyu; Mino, Barbara; Lu, Wei; Pandurengan, Renganayaki; Haymaker, Cara; Affolter, Kajsa; Scaife, Courtney L; Yip-Schneider, Michele; Schmidt, C Max; Firpo, Matthew A; Mulvihill, Sean J; Koay, Eugene J; Wang, Huamin; Wistuba, Ignacio I; Maitra, Anirban; Solis, Luisa M; Sen, Subrata.
Afiliação
  • Hernandez S; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Parra ER; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Uraoka N; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Tang X; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Shen Y; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Qiao W; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Jiang M; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Zhang S; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Mino B; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Lu W; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Pandurengan R; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Haymaker C; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Affolter K; Department of Pathology, University of Utah, Salt Lake City, Utah.
  • Scaife CL; Department of Surgery, University of Utah, Salt Lake City, Utah.
  • Yip-Schneider M; Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana.
  • Schmidt CM; Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana.
  • Firpo MA; Department of Surgery, University of Utah, Salt Lake City, Utah.
  • Mulvihill SJ; Department of Surgery, University of Utah, Salt Lake City, Utah.
  • Koay EJ; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Wang H; Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Wistuba II; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Maitra A; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Solis LM; Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Sen S; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Clin Cancer Res ; 28(9): 1938-1947, 2022 05 02.
Article em En | MEDLINE | ID: mdl-35491652
ABSTRACT

PURPOSE:

Intraductal papillary mucinous neoplasms (IPMN) are bona fide precursors to pancreatic ductal adenocarcinoma (PDAC). While genomic alterations during multistep IPMN progression have been well cataloged, the accompanying changes within the tumor immune microenvironment (TIME) have not been comprehensively studied. Herein, we investigated TIME-related alterations during IPMN progression, using multiplex immunofluorescence (mIF) coupled with high-resolution image analyses. EXPERIMENTAL

DESIGN:

Two sets of formalin-fixed, paraffin-embedded tissue samples from surgically resected IPMNs were analyzed. The training set of 30 samples consisted of 11 low-grade IPMN (LG-IPMN), 17 high-grade IPMN (HG-IPMN), and 2 IPMN with PDAC, while a validation set of 93 samples comprised of 55 LG-IPMN and 38 HG-IPMN. The training set was analyzed with two panels of immuno-oncology-related biomarkers, while the validation set was analyzed with a subset of markers found significantly altered in the training set.

RESULTS:

Cell types indicative of enhanced immune surveillance, including cytotoxic and memory T cells, and antigen-experienced T cells and B cells, were all found at higher densities within isolated LG-IPMNs compared with HG-IPMNs. Notably, the TIME of LG-IPMNs that had progressed at the time of surgical resection (progressor LGD) resembled that of the synchronous HG-IPMNs, underscoring that attenuated immune surveillance occurs even in LG-IPMNs destined for progression.

CONCLUSIONS:

Our findings provide a basis for interception of cystic neoplasia to PDAC, through maintenance of sustained immune surveillance using vaccines and other prevention approaches.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Adenocarcinoma Mucinoso / Carcinoma Ductal Pancreático / Neoplasias Intraductais Pancreáticas Tipo de estudo: Screening_studies Limite: Humans Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Adenocarcinoma Mucinoso / Carcinoma Ductal Pancreático / Neoplasias Intraductais Pancreáticas Tipo de estudo: Screening_studies Limite: Humans Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article